Review ArticleSystematic Review
Open Access

Prognostic role of secreted protein acidic and rich in cysteine in patients with solid tumors

Yongchen Ma, Hongbo Chen, Huiying Ma, Zihao Yao, Jianwen Hu, Ju Ma, Xiaoqian Zhang, Guowei Chen and Yucun Liu
Saudi Medical Journal August 2019, 40 (8) 755-765; DOI: https://doi.org/10.15537/smj.2019.8.24379

References

  1. ↵
    1. Hui LL,
    2. Chen Y
    (2015) Tumor microenvironment: Sanctuary of the devil. Cancer Lett 368:7–13.
    OpenUrlPubMed
  2. ↵
    1. Ma YC,
    2. Zhu J,
    3. Chen SW,
    4. Li TY,
    5. Ma J,
    6. Guo SH,
    7. et al.
    (2018) Activated gastric cancer-associated fibroblasts contribute to the malignant phenotype and 5-FU resistance via paracrine action in gastric cancer. Cancer Cell Int 18:104.
    OpenUrl
  3. ↵
    1. Sasaki T,
    2. Miosge N,
    3. Timpl R
    (1999) Immunochemical and tissue analysis of protease generated neoepitopes of BM-40 (osteonectin, SPARC) which are correlated to a higher affinity binding to collagens. Matrix Biol 18:499–508.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Jones C,
    2. Mackay A,
    3. Grigoriadis A,
    4. Cossu A,
    5. Reis-Filho JS,
    6. Fulford L,
    7. et al.
    (2004) Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 64:3037–3045.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Wong SLI,
    2. Sukkar MB
    (2017) The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease. Br J Pharmacol 174:3–14.
    OpenUrl
  6. ↵
    1. Said N
    (2016) Roles of SPARC in urothelial carcinogenesis, progression and metastasis. Oncotarget 7:67574–67585.
    OpenUrl
  7. ↵
    1. Nakashima S,
    2. Kobayashi S,
    3. Sakai D,
    4. Tomokuni A,
    5. Tomimaru Y,
    6. Hama N,
    7. et al.
    (2014) Prognostic impact of tumoral and/or peri-tumoral stromal SPARC expressions after surgery in patients with biliary tract cancer. J Surg Oncol 110:1016–1022.
    OpenUrlPubMed
  8. ↵
    1. Yu XZ,
    2. Guo ZY,
    3. Di Y,
    4. Yang F,
    5. Ouyang Q,
    6. Fu DL,
    7. et al.
    (2017) The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival. Hepatobiliary Pancreat Dis Int 16:104–109.
    OpenUrl
  9. ↵
    1. Zhu A,
    2. Yuan P,
    3. Du F,
    4. Hong R,
    5. Ding X,
    6. Shi X,
    7. et al.
    (2016) SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple-negative breast cancer. Oncotarget 7:76628–76634.
    OpenUrlPubMed
  10. ↵
    1. Kurtul N,
    2. Eroglu C,
    3. Unal D,
    4. Tasdemir EA,
    5. Orhan O,
    6. Zararsiz G,
    7. et al.
    (2014) Prognostic value of SPARC expression in unresectable NSCLC treated with concurrent chemoradiotherapy. Asian Pac J Cancer Prev 15:8911–8916.
    OpenUrl
  11. ↵
    1. Nakajima M,
    2. Yoshino S,
    3. Kanekiyo S,
    4. Maeda N,
    5. Sakamoto K,
    6. Tsunedomi R,
    7. et al.
    (2018) High secreted protein acidic and rich in cysteine expression in peritumoral fibroblasts predicts better prognosis in patients with resectable gastric cancer. Oncol Lett 15:803–812.
    OpenUrl
  12. ↵
    1. Perry AM,
    2. Cardesa-Salzmann TM,
    3. Meyer PN,
    4. Colomo L,
    5. Smith LM,
    6. Fu K,
    7. et al.
    (2012) A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood 120:2290–2296.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Moher D,
    2. Liberati A,
    3. Tetzlaff J,
    4. Altman DG,
    5. Grp P
    (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol 62:1006–1012.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Tierney JF,
    2. Stewart LA,
    3. Ghersi D,
    4. Burdett S,
    5. Sydes MR
    (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8.
  15. ↵
    1. Wells G,
    2. Shea B,
    3. O'Connell D,
    4. Peterson J,
    5. Welch V,
    6. Losos M
    The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses, Available from URL: http://wwwohrica/programs/clinical_epidemiology/oxfordhtm.
  16. ↵
    1. Gao YY,
    2. Han RB,
    3. Wang X,
    4. Ge SH,
    5. Li HL,
    6. Deng T,
    7. et al.
    (2015) Change of SPARC expression after chemotherapy in gastric cancer. Cancer Biol Med 12:33–40.
    OpenUrl
    1. Franke K,
    2. Carl-McGrath S,
    3. Roehl F-W,
    4. Lendeckel U,
    5. Ebert MPA,
    6. Taenzer M,
    7. et al.
    (2009) Differential Expression of SPARC in Intestinal-type Gastric Cancer Correlates with Tumor Progression and Nodal Spread. Transl Oncol 2:310–320.
    OpenUrlPubMed
  18. ↵
    1. Jeung HC,
    2. Rha SY,
    3. Im CK,
    4. Shin SJ,
    5. Ahn JB,
    6. Yang WI,
    7. et al.
    (2011) A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer 117:2050–2057.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Wu J,
    2. Zhang JR,
    3. Jiang XQ,
    4. Cao XG
    (2017) Correlation between secreted protein acidic and rich in cysteine protein expression and the prognosis of postoperative patients exhibiting esophageal squamous cell carcinoma. Mol Med Report 16:3401–3406.
    OpenUrl
  20. ↵
    1. Xue LY,
    2. Zou SM,
    3. Zheng S,
    4. Liu XY,
    5. Wen P,
    6. Yuan YL,
    7. et al.
    (2011) Expressions of the gamma2 chain of laminin-5 and secreted protein acidic and rich in cysteine in esophageal squamous cell carcinoma and their relation to prognosis. Chin J Cancer 30:69–78.
    OpenUrlPubMed
  21. ↵
    1. Sinn M,
    2. Sinn BV,
    3. Striefler JK,
    4. Lindner JL,
    5. Stieler JM,
    6. Lohneis P,
    7. et al.
    (2017) SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study. Ann Oncol 28:2900.
    OpenUrl
    1. Shintakuya R,
    2. Kondo N,
    3. Murakami Y,
    4. Uemura K,
    5. Nakagawa N,
    6. Okano K,
    7. et al.
    (2018) The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone. Pancreatology 18:191–197.
    OpenUrl
    1. Infante JR,
    2. Matsubayashi H,
    3. Sato N,
    4. Tonascia J,
    5. Klein AP,
    6. Riall TA,
    7. et al.
    (2007) Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25:319–325.
    OpenUrlAbstract/FREE Full Text
    1. Gundewar C,
    2. Sasor A,
    3. Hilmersson KS,
    4. Andersson R,
    5. Ansari D
    (2015) The role of SPARC expression in pancreatic cancer progression and patient survival. Scand J Gastroenterol 50:1170–1174.
    OpenUrl
  25. ↵
    1. Hidalgo M,
    2. Plaza C,
    3. Musteanu M,
    4. Illei P,
    5. Brachmann CB,
    6. Heise C,
    7. et al.
    (2015) SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. Clin Cancer Res 21:4811–4818.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Koukourakis MI,
    2. Giatromanolaki A,
    3. Brekken RA,
    4. Sivridis E,
    5. Gatter KC,
    6. Harris AL,
    7. et al.
    (2003) Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 63:5376–5380.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Komiya K,
    2. Nakamura T,
    3. Nakashima C,
    4. Takahashi K,
    5. Umeguchi H,
    6. Watanabe N,
    7. et al.
    (2016) SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer. Onco Targets Ther 9:6663–6668.
    OpenUrlPubMed
  28. ↵
    1. Kim YW,
    2. Park YK,
    3. Lee J,
    4. Ko SW,
    5. Yang MH
    (1998) Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci 13:652–657.
    OpenUrlPubMed
  29. ↵
    1. Kim JY,
    2. Jeong D,
    3. Ahn TS,
    4. Kim HJ,
    5. Park DS,
    6. Park SY,
    7. et al.
    (2013) Expression of Secreted Protein Acidic and Rich in Cysteine in the Stroma of a Colorectal Carcinoma is Associated With Patient Prognosis. Ann Coloproctol 29:93–99.
    OpenUrl
    1. Liang JF,
    2. Wang HK,
    3. Xiao H,
    4. Li N,
    5. Cheng CX,
    6. Zhao YZ,
    7. et al.
    (2010) Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res 29:71.
    OpenUrlCrossRefPubMed
    1. Liu QZ,
    2. Gao XH,
    3. Chang WJ,
    4. Wang HT,
    5. Wang H,
    6. Cao GW,
    7. et al.
    (2015) Secreted protein acidic and rich in cysteine expression in human colorectal cancer predicts postoperative prognosis. Eur Rev Med Pharmacol Sci 19:1803–1811.
    OpenUrl
  32. ↵
    1. Kurtul N,
    2. Tasdemir EA,
    3. Unal D,
    4. Izmirli M,
    5. Eroglu C
    (2017) SPARC: As a prognostic biomarker in rectal cancer patients treated with chemo-radiotherapy. Cancer Biomark 18:459–466.
    OpenUrl
  33. ↵
    1. Meyer PN,
    2. Fu K,
    3. Greiner T,
    4. Smith L,
    5. Delabie J,
    6. Gascoyne R,
    7. et al.
    (2011) The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol 135:54–61.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Wang HY,
    2. Li YY,
    3. Shao Q,
    4. Hou JH,
    5. Wang F,
    6. Cai MB,
    7. et al.
    (2012) Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis. J Transl Med 10:27.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Vaz J,
    2. Ansari D,
    3. Sasor A,
    4. Andersson R
    (2015) SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer. Pancreas 44:1024–1035.
    OpenUrl
  36. ↵
    1. Shin M,
    2. Mizokami A,
    3. Kim J,
    4. Ofude M,
    5. Konaka H,
    6. Kadono Y,
    7. et al.
    (2013) Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin beta1. Prostate 73:1159–1170.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Garber K
    (2010) Stromal Depletion Goes on Trial in Pancreatic Cancer. J Natl Cancer Inst 102:448–450.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Gong L,
    2. Mao W,
    3. Chen Q,
    4. Jiang Y,
    5. Fan YJCC
    (2019) Pharmacology. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study. Cancer Chemother Pharmacol 83:639–647.
    OpenUrl
  39. ↵
    1. Zhang J,
    2. Wang P,
    3. Zhu J,
    4. Wang W,
    5. Yin J,
    6. Zhang C,
    7. et al.
    (2014) SPARC expression is negatively correlated with clinicopathological factors of gastric cancer and inhibits malignancy of gastric cancer cells. Oncol Rep 31:2312–2320.
    OpenUrlPubMed
  40. ↵
    1. Morrissey MA,
    2. Jayadev R,
    3. Miley GR,
    4. Blebea CA,
    5. Chi Q,
    6. Ihara S,
    7. et al.
    (2016) SPARC Promotes Cell Invasion In Vivo by Decreasing Type IV Collagen Levels in the Basement Membrane. PLoS Genet 12:2.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section